258 related articles for article (PubMed ID: 32900797)
1. CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes.
Leuci V; Donini C; Grignani G; Rotolo R; Mesiano G; Fiorino E; Gammaitoni L; D'Ambrosio L; Merlini A; Landoni E; Medico E; Capellero S; Giraudo L; Cattaneo G; Iaia I; Pignochino Y; Basiricò M; Vigna E; Pisacane A; Fagioli F; Ferrone S; Aglietta M; Dotti G; Sangiolo D
Clin Cancer Res; 2020 Dec; 26(23):6321-6334. PubMed ID: 32900797
[TBL] [Abstract][Full Text] [Related]
2. CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma.
Giraudo L; Cattaneo G; Gammaitoni L; Iaia I; Donini C; Massa A; Centomo ML; Basiricò M; Vigna E; Pisacane A; Picciotto F; Berrino E; Marchiò C; Merlini A; Paruzzo L; Poletto S; Caravelli D; Biolato AM; Bortolot V; Landoni E; Ventin M; Ferrone CR; Aglietta M; Dotti G; Leuci V; Carnevale-Schianca F; Sangiolo D
J Exp Clin Cancer Res; 2023 Nov; 42(1):310. PubMed ID: 37993874
[TBL] [Abstract][Full Text] [Related]
3. Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas.
Sangiolo D; Mesiano G; Gammaitoni L; Leuci V; Todorovic M; Giraudo L; Cammarata C; Dell'Aglio C; D'Ambrosio L; Pisacane A; Sarotto I; Miano S; Ferrero I; Carnevale-Schianca F; Pignochino Y; Sassi F; Bertotti A; Piacibello W; Fagioli F; Aglietta M; Grignani G
Cancer Res; 2014 Jan; 74(1):119-29. PubMed ID: 24356422
[TBL] [Abstract][Full Text] [Related]
4. CD44v6 as innovative sarcoma target for CAR-redirected CIK cells.
Leuci V; Casucci GM; Grignani G; Rotolo R; Rossotti U; Vigna E; Gammaitoni L; Mesiano G; Fiorino E; Donini C; Pisacane A; Ambrosio LD; Pignochino Y; Aglietta M; Bondanza A; Sangiolo D
Oncoimmunology; 2018; 7(5):e1423167. PubMed ID: 29721373
[TBL] [Abstract][Full Text] [Related]
5. CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response.
Boudin L; de Nonneville A; Finetti P; Mescam L; Le Cesne A; Italiano A; Blay JY; Birnbaum D; Mamessier E; Bertucci F
J Transl Med; 2022 Oct; 20(1):464. PubMed ID: 36221119
[TBL] [Abstract][Full Text] [Related]
6. T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo.
Geldres C; Savoldo B; Hoyos V; Caruana I; Zhang M; Yvon E; Del Vecchio M; Creighton CJ; Ittmann M; Ferrone S; Dotti G
Clin Cancer Res; 2014 Feb; 20(4):962-71. PubMed ID: 24334762
[TBL] [Abstract][Full Text] [Related]
7. Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers.
Zuo S; Wen Y; Panha H; Dai G; Wang L; Ren X; Fu K
Mol Immunol; 2017 May; 85():293-304. PubMed ID: 28360017
[TBL] [Abstract][Full Text] [Related]
8. ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma.
Merker M; Wagner J; Kreyenberg H; Heim C; Moser LM; Wels WS; Bonig H; Ivics Z; Ullrich E; Klingebiel T; Bader P; Rettinger E
Front Immunol; 2020; 11():581468. PubMed ID: 33193388
[TBL] [Abstract][Full Text] [Related]
9. Effects of chondroitin sulfate proteoglycan 4 (NG2/CSPG4) on soft-tissue sarcoma growth depend on tumor developmental stage.
Hsu SC; Nadesan P; Puviindran V; Stallcup WB; Kirsch DG; Alman BA
J Biol Chem; 2018 Feb; 293(7):2466-2475. PubMed ID: 29196603
[TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
[TBL] [Abstract][Full Text] [Related]
11. Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System.
Rotiroti MC; Buracchi C; Arcangeli S; Galimberti S; Valsecchi MG; Perriello VM; Rasko T; Alberti G; Magnani CF; Cappuzzello C; Lundberg F; Pande A; Dastoli G; Introna M; Serafini M; Biagi E; Izsvák Z; Biondi A; Tettamanti S
Mol Ther; 2020 Sep; 28(9):1974-1986. PubMed ID: 32526203
[TBL] [Abstract][Full Text] [Related]
12. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
13. Modification of cytokine-induced killer cells with chimeric antigen receptors (CARs) enhances antitumor immunity to epidermal growth factor receptor (EGFR)-positive malignancies.
Ren X; Ma W; Lu H; Yuan L; An L; Wang X; Cheng G; Zuo S
Cancer Immunol Immunother; 2015 Dec; 64(12):1517-29. PubMed ID: 26386966
[TBL] [Abstract][Full Text] [Related]
14. Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy.
Pellegatta S; Savoldo B; Di Ianni N; Corbetta C; Chen Y; Patané M; Sun C; Pollo B; Ferrone S; DiMeco F; Finocchiaro G; Dotti G
Sci Transl Med; 2018 Feb; 10(430):. PubMed ID: 29491184
[TBL] [Abstract][Full Text] [Related]
15. Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation".
Hombach AA; Rappl G; Abken H
Mol Ther; 2013 Dec; 21(12):2268-77. PubMed ID: 23985696
[TBL] [Abstract][Full Text] [Related]
16. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced
Xu X; Huang W; Heczey A; Liu D; Guo L; Wood M; Jin J; Courtney AN; Liu B; Di Pierro EJ; Hicks J; Barragan GA; Ngai H; Chen Y; Savoldo B; Dotti G; Metelitsa LS
Clin Cancer Res; 2019 Dec; 25(23):7126-7138. PubMed ID: 31484667
[TBL] [Abstract][Full Text] [Related]
17. Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells.
Beard RE; Zheng Z; Lagisetty KH; Burns WR; Tran E; Hewitt SM; Abate-Daga D; Rosati SF; Fine HA; Ferrone S; Rosenberg SA; Morgan RA
J Immunother Cancer; 2014; 2():25. PubMed ID: 25197555
[TBL] [Abstract][Full Text] [Related]
18. Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas.
Long AH; Highfill SL; Cui Y; Smith JP; Walker AJ; Ramakrishna S; El-Etriby R; Galli S; Tsokos MG; Orentas RJ; Mackall CL
Cancer Immunol Res; 2016 Oct; 4(10):869-880. PubMed ID: 27549124
[TBL] [Abstract][Full Text] [Related]
19. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models.
Shi S; Wang R; Chen Y; Song H; Chen L; Huang G
PLoS One; 2013; 8(6):e65757. PubMed ID: 23799045
[TBL] [Abstract][Full Text] [Related]
20. Photothermal Therapy Promotes Tumor Infiltration and Antitumor Activity of CAR T Cells.
Chen Q; Hu Q; Dukhovlinova E; Chen G; Ahn S; Wang C; Ogunnaike EA; Ligler FS; Dotti G; Gu Z
Adv Mater; 2019 Jun; 31(23):e1900192. PubMed ID: 30916367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]